Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdV-HSV1-TK and AdV-Flt3L with Valacyclovir for Recurrent Malignant Brain Tumors
NCT06914479Phase 1Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2026
- Primary completion
- May 2031
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adenoviral Flt3L and Ad-hCMV-TK in brain tumor and diffuse hemispheric glioma (DHG), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Dose Limiting Toxicity. Started May 2026; status: recruiting.
02
Drugs
adenoviral Flt3LAd-hCMV-TK
03
Conditions
brain tumordiffuse hemispheric glioma (DHG)
Beyond the preview
Go deeper on NCT06914479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914479.